Sign in

Private company

Unity Biotechnology, Inc.

American pharmaceutical preparations company, incorporated in Delaware1

In its 2025 annual report the company says: “We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale. We have incurred significant losses since our inception, and we anticipate that we will continue to incur losses for the foreseeable future, which, together with our limited operating history, make it difficult to assess our future viability.”12 It is headquartered in South San Francisco, California.1

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersSouth San Francisco, California1
  • Incorporated inDE2
  • Business address285 East Grand Avenue, South San Francisco, Ca 940802
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-400.2%Return on equity3
-$20.9MFree cash flow3

Financial statements

Revenue4563$0 in 2024
0$2.0M$4.0M$6.0M2019: $0$020192020: $0$020202021: $4.8M$4.8M20212022: $236.0K$236.0K2022−95%2023: $0$020232024: $0$02024
Operating income74563-$31.2M in 2024−61% since 2018
-$100.0M-$75.0M-$50.0M-$25.0M02018: -$79.5M-$79.5M20182019: -$89.7M-$89.7M2019+13%2020: -$93.9M-$93.9M2020+5%2021: -$56.7M-$56.7M2021−40%2022: -$57.6M-$57.6M2022+2%2023: -$44.7M-$44.7M2023−22%2024: -$31.2M-$31.2M2024−30%
Net income74563-$26.0M in 2024−66% since 2018
-$100.0M-$75.0M-$50.0M-$25.0M02018: -$76.4M-$76.4M20182019: -$82.2M-$82.2M2019+8%2020: -$93.8M-$93.8M2020+14%2021: -$60.7M-$60.7M2021−35%2022: -$44.5M-$44.5M2022−27%2023: -$39.9M-$39.9M2023−10%2024: -$26.0M-$26.0M2024−35%
Fiscal year2018201920202021202220232024
Revenue$04$05$4.8M6$236.0K3$03$03
Research and development$58.9M7$71.0M4$67.3M5$38.4M6$36.9M3$20.1M3$13.0M3
Operating expenses$61.4M6$57.8M3$44.7M3$31.2M3
Operating income-$79.5M7-$89.7M4-$93.9M5-$56.7M6-$57.6M3-$44.7M3-$31.2M3
Interest$04$1.3M5$3.2M6$3.6M3$2.5M3$03
Net income-$76.4M7-$82.2M4-$93.8M5-$60.7M6-$44.5M3-$39.9M3-$26.0M3
Earnings per share-$18.455-$10.886-$4.683-$2.703-$1.543
Earnings per share (diluted)-$18.455-$10.886-$4.683-$2.703-$1.543
Shares (weighted, basic)5.6M shares69.5M shares314.8M shares316.8M shares3
Shares (weighted, diluted)5.6M shares69.5M shares314.8M shares316.8M shares3

Compare Unity Biotechnology, Inc. with another company

Corporate structure

Unity Biotechnology, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Unity Biotechnology, Inc.

  • Unity Biotechnology, Inc. South San Francisco, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Unity Biotechnology, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$12.7M3 Dec 31, 2024$14.3M3 Dec 31, 2023−11.5%
Accumulated depreciation$9.2M3 Dec 31, 2024$9.3M3 Dec 31, 2023−0.2%
Property and equipment, net$3.5M3 Dec 31, 2024$5.1M3 Dec 31, 2023−32.0%
Operating-lease assets (leased space)$8.9M3 Dec 31, 2024$13.0M3 Dec 31, 2023−31.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$7.6M3 Dec 31, 2024$19.8M3 Dec 31, 2023−61.7%
Marketable securities, current$15.7M3 Dec 31, 2024$23.4M3 Dec 31, 2023−33.1%
Debt securities available for sale$23.0M3 Dec 31, 2024$40.1M3 Dec 31, 2023−42.8%

Properties, in its own words

Our corporate headquarters are located in South San Francisco, California, where we currently lease approximately 62,000 square feet of office and laboratory space pursuant to a lease dated February 28, 2019, of which approximately 23,000 square feet was subleased from June 2021 through July 2024 and approximately 15,000 square feet was subleased as of July 2022 through June 2026 with an additional 17,000 square feet subleased as of September 2023 through June 2026. The majority of our employees work at our corporate headquarters.

Item 2 of the 10-K filed Mar 7, 2025.12

Leadership

Who has led Unity Biotechnology, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Keith R. Leonard2018–2020
  2. Anirvan Ghosh2020–now

President

  1. Craig R. Jalbert2025–now

Chief financial officer

  1. Robert C. Goeltz Ii.2018–2020
  2. Lynne Marie Sullivan2020–now
20202025
Board members and other officers (21)

Former names

  • Cenexys, Inc.Jul 15, 2013 to Jul 15, 20132
  • Forge IncMay 5, 2009 to May 5, 20092

Timeline

  1. Sep 26, 20258-K Ended a material agreement; Change to shareholders' rights36
  2. Sep 19, 20258-K Shareholder vote37
  3. Jul 24, 20258-K Entered a material agreement; Unregistered sale of shares; Change to shareholders' rights38
  4. Jul 22, 20258-K Entered a material agreement; Unregistered sale of shares; Change to shareholders' rights39
  5. Jun 30, 20258-K Listing notice or transfer; Executive or director change; Other events40
  6. Jun 20, 20258-K Listing notice or transfer41
  7. May 5, 20258-K Exit or restructuring costs; Executive or director change; Other events42
  8. Apr 22, 20258-K Results of operations43
  9. Apr 4, 20258-K Executive or director change44
  10. Mar 24, 20258-K Other events45
  11. Mar 17, 20258-K Listing notice or transfer46
  12. Mar 10, 20258-K Change in control; Other events47
  13. Apr 1, 2020New chief executive Anirvan Ghosh becomes CEO13
  14. May 2, 2018New chief executive Keith R. Leonard becomes CEO14

Calendar

When it reported results

  1. Apr 22, 2025Reported quarterly or annual results43
  2. Mar 7, 2025Reported quarterly or annual results48
  3. Nov 4, 2024Reported quarterly or annual results49
  4. Aug 6, 2024Reported quarterly or annual results50
  5. May 14, 2024Reported quarterly or annual results51
  6. Apr 15, 2024Reported quarterly or annual results52
  7. Nov 13, 2023Reported quarterly or annual results53
  8. Aug 8, 2023Reported quarterly or annual results54

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

244 filings to the SEC since October 2021: 5 annual reports, 11 quarterly reports, 52 major events, 98 insider forms, 12 large holders, 66 other. The latest 20:

  1. Jan 2, 202615-12G EDGAR
  2. Nov 14, 2025SCHEDULE 13G/A EDGAR
  3. Sep 26, 2025EFFECT EDGAR
  4. Sep 26, 2025EFFECT EDGAR
  5. Sep 26, 20258-K EDGAR
  6. Sep 25, 2025POS AM EDGAR
  7. Sep 25, 2025POS AM EDGAR
  8. Sep 19, 20258-K EDGAR
  9. Aug 25, 2025S-8 POS EDGAR
  10. Aug 25, 2025S-8 POS EDGAR
  11. Aug 25, 2025S-8 POS EDGAR
  12. Aug 25, 2025S-8 POS EDGAR
  13. Aug 25, 2025S-8 POS EDGAR
  14. Aug 25, 2025S-8 POS EDGAR
  15. Aug 25, 2025S-8 POS EDGAR
  16. Aug 25, 2025S-8 POS EDGAR
  17. Aug 25, 2025S-8 POS EDGAR
  18. Aug 25, 2025S-8 POS EDGAR
  19. Aug 11, 2025DEF 14A EDGAR
  20. Aug 1, 2025PRE 14A EDGAR

The 244 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

44 open-market trades by officers, directors and large owners since October 2021: 0 buys and 44 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 2, 2025Nguyen Alexander HieuCLO and Head of OpsSale17,852$1.03$18.4KForm 4
Apr 2, 2025Sullivan Lynne MarieCFO & Head of Corp. Dev.Sale21,867$1.03$22.5KForm 4
Apr 2, 2025Ghosh AnirvanChief Executive OfficerSale96,797$1.03$99.7KForm 4
Mar 27, 2025Nguyen Alexander HieuCLO and Head of OpsSale1,954$1.16$2.3KForm 4
Feb 4, 2025Sullivan Lynne MarieCFO & Head of Corp. Dev.Sale153$2.23$341Form 4
Feb 4, 2025Nguyen Alexander HieuCLO and Head of OpsSale164$2.23$366Form 4
Feb 4, 2025Ghosh AnirvanChief Executive OfficerSale642$2.23$1.4KForm 4
Nov 4, 2024Sullivan Lynne MarieCFO & Head of Corp. Dev.Sale136$1.29$175Form 4
Nov 4, 2024Nguyen Alexander HieuCLO and Head of OpsSale149$1.29$192Form 4
Nov 4, 2024Ghosh AnirvanChief Executive OfficerSale432$1.29$557Form 4
Aug 2, 2024Nguyen Alexander HieuCLO and Head of OpsSale154$1.53$236Form 4
Aug 2, 2024Ghosh AnirvanChief Executive OfficerSale604$1.53$924Form 4
Aug 2, 2024Sullivan Lynne MarieCFO & Head of Corp. Dev.Sale139$1.53$213Form 4
Jun 25, 2024Nguyen Alexander HieuCLO and Head of OpsSale78$1.40$109Form 4
Jun 25, 2024Ghosh AnirvanChief Executive OfficerSale1,214$1.40$1.7KForm 4
Jun 25, 2024Sullivan Lynne MarieCFO & Head of Corp. Dev.Sale324$1.40$454Form 4
May 2, 2024Ghosh AnirvanChief Executive OfficerSale603$1.55$935Form 4
Feb 2, 2024Ghosh AnirvanChief Executive OfficerSale680$1.71$1.2KForm 4
Jan 30, 2024Ghosh AnirvanChief Executive OfficerSale1,183$1.71$2.0KForm 4
Nov 2, 2023Ghosh AnirvanChief Executive OfficerSale589$1.83$1.1KForm 4

All 44 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Unity Biotechnology, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARUnity Biotechnology, Inc.1
  • CIK0001463361
  • Employer ID (EIN)26-472603512
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company12
  • Incorporated inDelaware12
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address285 East Grand Avenue, South San Francisco, CA 940801
  • Phone(650) 416-11921
  • Shares outstanding17,212,172 as of Apr 18, 20258
  • Public float$22.5M as of Jun 30, 202412
  • AuditorErnst & Young LLP, San Mateo, California PCAOB ID 42; no auditor attestation of internal control over financial reporting12
  • On EDGAR sinceMay 5, 20091
  • Filings464 in all: 4 (178), 8-K (86), 3 (23), 10-Q (22), SC 13G/A (18), 144 (11), S-8 (10), S-8 POS (10)1
    All 39 form types

    SC 13G (10), 424B5 (9), CORRESP (9), DEF 14A (8), 10-K (7), DEFA14A (7), EFFECT (7), UPLOAD (6), CT ORDER (5), D (5), 8-K/A (4), S-3 (4), PRE 14A (3), 5 (2), ARS (2), POS AM (2), SCHEDULE 13G/A (2), 10-K/A (1), 15-12G (1), 25-NSE (1), 424B3 (1), 424B4 (1), 8-A12B (1), CERT (1), D/A (1), DRS (1), DRS/A (1), FWP (1), NT 10-K (1), S-1 (1), S-1/A (1)

  • Latest filingsAnnual report (10-K) Mar 7, 2025
    Quarterly report (10-Q) Apr 22, 2025
    Proxy statement (DEF 14A) Aug 11, 2025
    Latest 8-K (8-K) Sep 26, 2025

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.0001UBXThe Nasdaq Global Select Market

From the cover page of the 10-K filed Mar 7, 2025 (Section 12(b) of the Exchange Act).12

Risk factors and legal proceedings

The risks Unity Biotechnology, Inc. names in Item 1A of its 10-K filed Mar 7, 2025: 55 risks under these headings, as written.12

  • Risks Related to Our Limited Operating History, Financial Condition, and Capital Requirements
  • We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale. We have incurred significant losses since our inception, and we anticipate that we will continue to incur losses for the foreseeable future, which, together with our limited operating history, make it difficult to assess our future viability.
  • Our financial condition raises substantial doubt as to our ability to continue as a going concern.
  • We will require substantial additional financing to achieve our goals, and a failure to obtain this capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, other operations or commercialization efforts.
  • We may not be able to maintain compliance with the continued listing requirements of Nasdaq, and, if so, we would be subject to delisting.
  • Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations.
  • Risks Related to Our Business and Product Development
  • Our core therapeutic approach to slow, halt, or reverse diseases of aging is based on our understanding of cellular senescence. Utilizing senolytic molecules to treat diseases of aging is a novel therapeutic approach, which exposes us to unforeseen risks and makes it difficult to predict the time and cost of drug development and potential for regulatory approval.
  • Our business is currently dependent on the successful development of UBX1325, which is in Phase 2 of clinical development.
  • Other than UBX1325, all of our other programs are preclinical and face significant development risk.
  • Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.
  • If we encounter difficulties enrolling patients in our clinical studies, our clinical development activities could be delayed or otherwise adversely affected.
The other 44 risks
  • Interim, “top-line” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain, or deploy key leadership and other personnel, or otherwise prevent products
  • from being developed, approved, or commercialized in a timely manner or at all, which may adversely affect our business.
  • Our drug candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.
  • We may not be successful in our efforts to continue to create a pipeline of drug candidates or to develop commercially successful products. If we fail to successfully identify and develop additional drug candidates, our commercial opportunity may be limited.
  • We may be unable to obtain regulatory approval for our drug candidates under applicable regulatory requirements. The denial or delay of any such approval would delay commercialization of our drug candidates and adversely impact our potential to generate revenue, our business and our results of operations.
  • Even if our current drug candidates or any future drug candidates obtain regulatory approval, they may fail to achieve the broad degree of physician and patient adoption and use necessary for commercial success.
  • We rely on third-party suppliers to manufacture supplies of our drug candidates and we intend to continue to rely on third parties to produce such preclinical and clinical supplies as well as commercial supplies of any approved product. The loss of these suppliers, or their failure to comply with applicable regulatory requirements or to provide us with sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.
  • If we fail to attract and retain key personnel, we may be unable to successfully develop our current drug candidates or any future drug candidates, conduct our clinical studies and commercialize our current or any future drug candidates.
  • We depend on third-party suppliers for key raw materials used in our manufacturing processes, and the loss of these third-party suppliers or their inability to supply us with adequate raw materials could harm our business.
  • We face significant competition in an environment of rapid technological and scientific change, and our drug candidates, if approved, will face significant competition and our failure to effectively compete may prevent us from achieving significant market penetration. Most of our competitors have significantly greater resources than we do, and we may not be able to successfully compete.
  • The successful commercialization of our drug candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our drug candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.
  • We currently have no sales organization. If we are unable to establish sales capabilities on our own or through third parties, we may not be able to market and sell our drug candidates effectively in the U.S. and foreign jurisdictions, if approved, or generate product revenue.
  • If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our current or future drug candidates.
  • Our existing collaborations as well as additional collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our drug candidates.
  • Risks Related to Intellectual Property
  • Our senolytic medicine platform and any future products that we commercialize could be alleged to infringe patent rights and other proprietary rights of third parties, which may require costly litigation and, if we are not successful, could cause us to pay substantial damages and/or limit our ability to commercialize our products.
  • If we are unable to obtain, maintain and enforce intellectual property protection directed to our senolytic medicine platform and any future technologies that we develop, others may be able to make, use, or sell products substantially the same as ours, which could adversely affect our ability to compete in the market.
  • Our intellectual property agreements with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors.
  • If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected.
  • Risks Related to Government Regulation
  • Even if we obtain regulatory approval for a drug candidate, our products will remain subject to regulatory scrutiny.
  • If any of our small molecule drug candidates obtain regulatory approval, additional competitors could enter the market with generic versions of such drugs, which may result in a material decline in sales of affected products.
  • Any biologic, or large molecule, drug candidates for which we intend to seek approval may face competition sooner than anticipated.
  • Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our drug candidates and may affect the prices we may set.
  • Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.
  • U.S. tax legislation and future changes to applicable U.S. tax laws and regulations may have a material adverse effect on our business, financial condition and results of operations.
  • Risks Related to Ownership of Our Common Stock
  • Our stock price may be volatile and you may not be able to resell shares of our common stock at or above the price you paid.
  • An active, liquid and orderly market for our common stock may not be maintained.
  • If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.
  • If we sell shares of our common stock in future financings, stockholders may experience immediate dilution and, as a result, our stock price may decline.
  • We have identified a material weakness in our internal control over financial reporting. This material weakness could continue to adversely affect our results of operations and financial condition. In the future, we may identify additional material weaknesses or otherwise fail to maintain an effective system of internal control over financial reporting or adequate disclosure controls and procedures, which may result in material errors in our financial statements or cause us to fail to meet our period reporting obligations.
  • Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
  • Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.
  • Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.
  • We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.
  • General Risk Factors
  • Unfavorable global economic or political conditions could adversely affect our business, financial condition or results of operations.
  • We or the third parties upon whom we depend may be adversely affected by earthquakes, other natural disasters or unforeseen pandemics and public health emergencies, such as the COVID-19 pandemic, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.
  • Significant disruptions of information technology systems or deficiencies in our cybersecurity could materially adversely affect our business, results of operations and financial condition.
  • Our employees and independent contractors, including principal investigators, consultants, commercial collaborators, service providers and other vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations.
  • Our business involves the use of hazardous materials, and we and our third-party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business.
  • We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
  • We may not be able to protect our intellectual property rights throughout the world.
  • Actual or perceived failures to comply with U.S. and foreign privacy and data protection laws, regulations and standards may adversely affect our business, operations and financial performance.
  • We incur increased costs as a result of operating as a public company, and our management devote substantial time to new compliance initiatives. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, which could result in sanctions or other penalties that would harm our business.
  • We have recorded, and may be required to record in the future, significant charges if our long-lived assets become impaired.

Legal proceedings

We are not currently a party to any material litigation or other material legal proceedings.

The opening of Item 3, Legal Proceedings.12

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
    SEC EDGAROther events
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58